AB0979 Eosinophilic fascitis: clinical experience in a series of 21 patients. (15th June 2017)

• Record Type: Journal Article
• Authors: Quevedo, JC; Lopez, R; Garcia-Bustuinduy, M; Rodriguez-Lozano, C; Rodriguez-Lozano, B; Bustabad, S; Trujillo, E
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 1397
• Page End: 1397
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.6444
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The Eosinophilic fascitis (EF) is a uncommon sclerodermiforme síndrome with unknown etiology and poorly understood pathogenesis and natural evolution. The published series are short, with a total of 280 cases described in the literature from 1974. There is neither clinical tests nor consensus on the EF treatment. Objectives: To describe a series of 21 patients with EF. Methods: Multicentric, retrospective Case Series Study. We reviewed 21 patients diagnosed of EF (cutaneous induration+consistent biopsy) between January 1998 to January 2015. A total of 13 males and 8 females. Results: The mean age at diagnosis was 41 years 8range between 28 and 66). Trigger factor was suspected in 8 patients (intense exercise in 7). The zones of cutaneous affectation were fundamentally the upper and low extremities. The hyperesonophilia was present in 100% of the patients. The average of the % more high of hyperesosinophilia was 21.2% (range 4–45.4%). 11 patients presented artralgias and 5 patients presented arthritis (4 polyarticular/1 oligoarticular). The MRI was used for diagnosis and/or follow-up in 8 patients, especially in the diagnosed ones in the last 5 years. The average initial dose of prednisone was 40 mg/día, the average maximum dose of prednisone was 40 mg/dia and the mean steroid treatment duration was 22 months (range 9–47 months). Other immunomodulatory agents were: methotrexate 11, hydroxychloroquine 2, azatioprina 2 and D penicillamine 1. 5 years after follow-up, the evolution was the complete resolution in 13 patients and the partial improvement in 6. Conclusions: In our series, the EF prevails in males, in the decade of the 40 and in the majority one did not find trigger factor. There was presence of arthritis in a significant percentage of patients. In the last years the use of the RMN has been added to the diagnosis and to the follow-up. Though there are no clinical tests that support it the use of the metotrexato has been generalized as adjuvant treatment to the steroids. Disclosure of Interest: None declared